California Retina Consultants
Santa Maria, California 93454
0 studies enrolling now · 16 studies all time
What they study most
Age-Related Macular Degeneration, Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema, Dry Age-related Macular Degeneration, Dry Macular Degeneration, Geographic Atrophy, Macular Degeneration, Macular Degeneration, Age-Related, Macular Edema, Neovascular Age-related Macular Degeneration, Nonproliferative Diabetic Retinopathy
Studies at this site
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) — Completed
- Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration — Completed
- A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema — Completed
- A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) — Stopped early
- A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. — Stopped early
- ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA — Completed
- A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) — Completed
- The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) — Completed
- Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD — Completed
- First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration — Completed
- INtravitreal and Aqueous Dexamethasone Levels After DEXtenza — Status unconfirmed
- Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema — Completed
- Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab — Completed
- Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab — Completed
- Lucentis for Central Retinal Vein Occlusion (CRVO) — Completed
- Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion — Completed